Intellia Therapeutics (NTLA) Enterprise Value (2015 - 2026)
Intellia Therapeutics (NTLA) reported Enterprise Value of -$376.0 million for Q1 2026, up 25.36% year-over-year from -$299.9 million in Q1 2025, and up 16.43% on a QoQ basis from -$449.9 million in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of Enterprise Value data on file, last reported at -$376.0 million in Q1 2026.
- Quarterly Enterprise Value rose 25.36% year-over-year to -$376.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$376.0 million (up 25.36% YoY) and the FY2025 annual result came in at -$449.9 million, up 25.21% from the prior year.
- Enterprise Value rose to -$376.0 million in Q1 2026 per NTLA's latest filing, from -$449.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$376.0 million in Q1 2026 and bottomed at -$1.2 billion in Q4 2022.
- The 5-year median for Enterprise Value is -$791.3 million (2024), against an average of -$729.5 million.
- The widest annual swing landed in 2022, when Enterprise Value plunged 65.26%; it then surged 36.34% in 2025.
- Tracing NTLA's Enterprise Value over 5 years: stood at -$1.2 billion in 2022, then rose by 23.51% to -$912.2 million in 2023, then soared by 34.06% to -$601.5 million in 2024, then gained by 25.21% to -$449.9 million in 2025, then advanced by 16.43% to -$376.0 million in 2026.
- Per Business Quant, the three latest NTLA Enterprise Value figures stand at -$376.0 million (Q1 2026), -$449.9 million (Q4 2025), and -$511.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -375.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -375.99 Mn |
| Dec 31, 2025 | -449.88 Mn |
| Sep 30, 2025 | -511.04 Mn |
| Jun 30, 2025 | -459.65 Mn |
| Mar 31, 2025 | -503.75 Mn |
| Dec 31, 2024 | -601.52 Mn |
| Sep 30, 2024 | -658.11 Mn |
| Jun 30, 2024 | -691.07 Mn |
| Mar 31, 2024 | -791.29 Mn |
| Dec 31, 2023 | -912.22 Mn |
| Sep 30, 2023 | -854.79 Mn |
| Jun 30, 2023 | -908.07 Mn |
| Mar 31, 2023 | -933.54 Mn |
| Dec 31, 2022 | -1.19 Bn |
| Sep 30, 2022 | -828.19 Mn |
| Jun 30, 2022 | -874.28 Mn |
| Mar 31, 2022 | -855.25 Mn |
| Dec 31, 2021 | -750.77 Mn |
| Sep 30, 2021 | -798.27 Mn |
| Jun 30, 2021 | -529.02 Mn |
| Mar 31, 2021 | -584.06 Mn |
| Dec 31, 2020 | -597.37 Mn |
| Sep 30, 2020 | -407.95 Mn |
| Jun 30, 2020 | -436.80 Mn |
| Mar 31, 2020 | -250.26 Mn |
| Dec 31, 2019 | -279.73 Mn |
| Sep 30, 2019 | -285.92 Mn |
| Jun 30, 2019 | -271.10 Mn |
| Mar 31, 2019 | -47.10 Mn |
| Dec 31, 2018 | -314.06 Mn |
| Sep 30, 2018 | -293.25 Mn |
| Jun 30, 2018 | -305.54 Mn |
| Mar 31, 2018 | -327.78 Mn |
| Dec 31, 2017 | -340.68 Mn |
| Sep 30, 2017 | -222.26 Mn |
| Jun 30, 2017 | -241.05 Mn |
| Mar 31, 2017 | -257.55 Mn |
| Dec 31, 2016 | -273.06 Mn |
| Sep 30, 2016 | -290.62 Mn |
| Jun 30, 2016 | -300.69 Mn |
| Mar 31, 2016 | -64.19 Mn |
| Dec 31, 2015 | -75.82 Mn |
| Sep 30, 2015 | -82.61 Mn |
| Jun 30, 2015 | -19.77 Mn |
| Mar 31, 2015 | -18.48 Mn |